Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP Group Swings To Loss In First-Half On Reduction In Portfolio Gains

Wed, 25th Jul 2018 09:39

LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.

The intellectual property-based business developer said pretax loss for six months to the end of June was GBP21.6 million, swinging from a pretax profit of GBP16.7 million for the same period the year previously.

This was due to a change in the fair value of its equity and debt investments to GBP700,000, from a fair value gain of GBP28.5 million the year before.

Licensing income more than halved to GBP800,000 million from GBP3.0 million the year before, while the fair value of its portfolio nearly doubled to GBP1.16 billion from GBP663.0 million year-on-year.

The single largest portfolio company fair value increase during the period was Diurnal Group PLC in the Life Sciences sector.

The London-listed pharmaceutical company hit a major milestone this year, moving it from a development company onto marketing and sales, after Infacort medicine was approved for marketing by the European Commission. An increase in the share price of Diurnal resulted in a fair value increase of GBP10.2 million to IP Group.

During the first half of 2018, IP Group said it deployed GBP46.9 million of capital into 41 portfolio companies and projects.

"The underlying performance of the group's portfolio has been robust in the first half with a number of our companies completing both major fundraisings and collaborations," said Chief Executive Alan Aubrey.

"The group remains excited by the opportunities within the portfolio and we look to the second half of the year and beyond with confidence," added Aubrey.

Shares in IP Group were trading 2.6% lower on Wednesday at 126.96 pence each.

More News
18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

Read more
3 Apr 2018 16:19

Diurnal To Raise GBP10.5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said on Tuesday that it intends to raise GBP10.5 million through the placing of different types of shares.The

Read more
20 Mar 2018 18:28

Diurnal Nets GBP500,000 From Broker Option Exercise (ALLISS)

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Tuesday said that it has received a letter of notice to exercise the broker option in respect of 263,157 in

Read more
12 Mar 2018 13:51

UPDATE: Diurnal Prepares For First Revenue As Appoints Trial Partner

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Monday appointed a clinical trial services provider for its Chronocort treatment, as it posted a widened loss

Read more
12 Mar 2018 10:18

Diurnal Interim Loss Widens On Cost Rise As Prepares For First Revenue

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Monday its interim loss widened amid a rise in research and administrative expenses, as it prepares to its

Read more
12 Mar 2018 05:17

UK Stocks-Factors to watch on March 12

March 12 (Reuters) - Britain's FTSE 100 index is seen opening up 8 points higher at 7,233 on Monday, according to financial bookmakers. * GKN-MELROSE: GKN has struck a deal

Read more
25 Jan 2017 09:31

Diurnal Agrees Two Deals With UDG Healthcare Ahead Of Infacort Launch

Read more
17 Jan 2017 15:43

DIRECTOR DEALINGS: Diurnal Non-Executive Ups Interest

Read more
16 Jan 2017 15:08

Director dealings: Diurnal trio dip in after EMA submission in December

(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year. Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a pri

Read more
12 Jan 2017 09:04

Diurnal Hires Outgoing Mereo BioPharma Finance Chief Bungay

Read more
20 Dec 2016 12:23

Diurnal Submits European Marketing Application For Infacort

Read more
21 Nov 2016 09:32

Diurnal Doses First Testosterone Replacement Therapy Trial Patients

Read more
5 Oct 2016 15:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
11 Jul 2016 08:00

Diurnal and IP Group eye 2017 launch for childhood hormonal treatment

(ShareCast News) - Diurnal Group, 45%-owned by university spin-out specialist IP Group, has produced positive clinical trial results for its treatment for a rare hormonal disease in young children. A European Phase III study for AIM-quoted Diurnal's Infacort treatment for paediatric Adrenal Insuffic

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.